SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D. R., Dittmar, K., Kolitz, J. E., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,634

Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., & Schlossman, S. F. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1588 · Cited by 1,629

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983

Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells

Terstappen, L. W. M. M., Huang, S., Safford, M., Lansdorp, P., & Loken, M. R. (1991) · Blood · doi:10.1182/blood.v77.6.1218.1218 · Cited by 845

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease

Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z. A., Thomas, P., Stevenson, F. K., & Oscier, D. G. (2002) · Blood · doi:10.1182/blood.v99.3.1023 · Cited by 618

Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

Ibrahim, S., Keating, M. J., Do, K.-A., O'Brien, S. M., Huh, Y. O., Jilani, I. B., Lerner, S. A., Kantarjian, H. M., & Albitar, M. X. (2001) · Blood · doi:10.1182/blood.v98.1.181 · Cited by 451

CD38 and CD157: A long journey from activation markers to multifunctional molecules

Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V. K., Ferrero, E., Funaro, A., Horenstein, A. L., & Malavasi, F. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21092 · Cited by 269

Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity.

Graeff, R. M., Walseth, T. F., Fryxell, K., Branton, W. D., & Lee, H. C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43806-9 · Cited by 243

Humanization of murine monoclonal antibodies through variable domain resurfacing.

Roguska, M., Pedersen, J. T., Keddy, C., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R., & Guild, B. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.969 · Cited by 208

Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Dotan, E., Aggarwal, C., & Smith, M. R. (2010) · PubMed Central · Cited by 166

Crystal Structure of Human CD38 Extracellular Domain

Liu, Q., Kriksunov, I. A., Graeff, R. M., Munshi, C. B., Lee, H. C., & Hao, Q. (2005) · Structure · doi:10.1016/j.str.2005.05.012 · Cited by 164

CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells

Zupo, S., Rugari, E., Dono, M., Taborelli, G., Malavasi, F., & Ferrarini, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240532 · Cited by 151

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia

Deaglio, S., Vaisitti, T., Aydin, S., Ferrero, E., & Malavasi, F. (2006) · Blood · doi:10.1182/blood-2006-01-013003 · Cited by 145

Novel CD20 monoclonal antibodies for lymphoma therapy

Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-64 · Cited by 140

The future of anti-CD20 monoclonal antibodies: are we making progress?

Alduaij, W., & Illidge, T. (2011) · Blood · doi:10.1182/blood-2010-07-298356 · Cited by 131

New Strategies in the Treatment of Multiple Myeloma

Munshi, N. C., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1881 · Cited by 127

Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond

Bello, C. M., & Sotomayor, E. M. (2007) · Hematology · doi:10.1182/asheducation-2007.1.233 · Cited by 118

CD38/CD19: a lipid raft–dependent signaling complex in human B cells

Deaglio, S., Vaisitti, T., Billington, R. A., Bergui, L., Omedè, P., Genazzani, A. A., & Malavasi, F. (2007) · Blood · doi:10.1182/blood-2006-12-061812 · Cited by 118

CD38 is functionally dependent on the TCR/CD3 complex in human T cells

Morra, M., Zubiaur, M., Terhorst, C., Sancho, J., & Malavasi, F. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.581 · Cited by 113

Human CD38 is an authentic NAD(P)+ glycohydrolase

Berthelier, V., Tixier, J. M., Muller‐Steffner, H., Schuber, F. J., & Déterre, P. (1998) · Biochemical Journal · doi:10.1042/bj3301383 · Cited by 109

Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody

Stevenson, F. K., Bell, A. J., Cusack, R., Hamblin, T. J., Cj, S., Spellerberg, M. B., & Stevenson, G. (1991) · Blood · doi:10.1182/blood.v77.5.1071.1071 · Cited by 94

Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma

Ellis, J. H., Barber, K. A., Tutt, A. N. J., Hale, C., Lewis, A., Glennie, M. J., Stevenson, G. T., & Crowe, J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.2.925 · Cited by 81

The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38

Ferrero, E., & Malavasi, F. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.2.151 · Cited by 79

Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments]

Goldmacher, V. S., Bourret, L., Levine, B., Rasmussen, R., Pourshadi, M., Lambert, J., & Anderson, K. C. (1994) · Blood · doi:10.1182/blood.v84.9.3017.3017 · Cited by 76

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Lisby, S., & Richardson, P. G. G. (2012) · Blood · doi:10.1182/blood.v120.21.73.73 · Cited by 70

ADP-Ribosyl Cyclase and CD38

Lee, H. C., Graeff, R. M., & Walseth, T. F. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8632-0_53 · Cited by 68

Structural Basis for the Mechanistic Understanding of Human CD38-controlled Multiple Catalysis

Liu, Q., Kriksunov, I. A., Graeff, R. M., Munshi, C. B., Lee, H. C., & Hao, Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606365200 · Cited by 62

Discontinuous expression of a membrane antigen (HB‐7) during B lymphocyte differentiation

Tedder, T. F., Clement, L. T., & Cooper, M. D. (1984) · Tissue Antigens · doi:10.1111/j.1399-0039.1984.tb02118.x · Cited by 62

A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody

Gazzano, H., Ralph, P., Ryskamp, T., Chen, A. B., & Mukku, V. R. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00002-1 · Cited by 55

CD38 expressed on human monocytes: A coaccessory molecule in the superantigen-induced proliferation

Zilber, M.-T., Gregory, S., Mallone, R., Deaglio, S., Malavasi, F., Charron, D. J., & Gélin, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050583197 · Cited by 51

Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus

Hoshino, S.-I., Kukimoto, I., Kontani, K., Inoue, S., Kanda, Y., Malavasi, F., & Katada, T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.741 · Cited by 51

Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes

Lee, H. C., Munshi, C. B., & Graeff, R. M. (1999) · Springer eBooks · doi:10.1007/978-1-4419-8740-2_13 · Cited by 41

Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes

Lee, H. C., Munshi, C. B., & Graeff, R. M. (1999) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006916311348 · Cited by 38

The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

Endell, J., Boxhammer, R., Wurzenberger, C., Ness, D., & Steidl, S. (2012) · Blood · doi:10.1182/blood.v120.21.4018.4018 · Cited by 37

Antibody therapy for treatment of multiple myeloma.

Maloney, D. G., Donovan, K. A., & Hamblin, T. J. (1999) · PubMed · Cited by 36

Ligation of Cell Surface CD38 Protein with Agonistic Monoclonal Antibody Induces a Cell Growth Signal in Myeloid Leukemia Cells

Konopleva, M. Y., Estrov, Z. E., Zhao, S., Andreeff, M., & Mehta, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4702 · Cited by 34

SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

Martin, T. G., Strickland, S. A., Glenn, M. J., Zheng, W., Daskalakis, N., & Mikhael, J. R. (2013) · Blood · doi:10.1182/blood.v122.21.284.284 · Cited by 33

CD38-Mediated Signaling Events in Murine Pro-B Cells Expressing Human CD38 With or Without Its Cytoplasmic Domain

Kitanaka, A., Suzuki, T., Ito, C., Nishigaki, H., Coustan‐Smith, E., Tanaka, T., Kubota, Y., & Campana, D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.1952 · Cited by 32

CD38 in Hematopoietic Malignancies

Konopleva, M. Y., Rissling, I., & Andreeff, M. (2000) · KARGER eBooks · doi:10.1159/000058769 · Cited by 27

Functional topography of discrete domains of human CD38

Ausiello, C. M., Urbani, F., Lande, R., Sala, A. L., Carlo, B. D., Baj, G., Surico, N., Hilgers, J., Deaglio, S., Funaro, A., et al. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.560608.x · Cited by 24

Perspectives in the treatment of multiple myeloma

Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 22

Phagocytosis Is A Mechanism of Action for Daratumumab

Overdijk, M. B., Verploegen, S. A. B. W., Bögels, M., van Egmond, M., Groen, R. W. J., Martens, A. C., van Bueren, J. J. L., Bleeker, W. K., & Parren, P. W. H. I. (2012) · Blood · doi:10.1182/blood.v120.21.4054.4054 · Cited by 19

Fully human antibody MOR202 against CD38 for the treatment of multiple myeloma and other blood-borne malignancies

Tesar, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8106 · Cited by 15

Conformational Closure of the Catalytic Site of Human CD38 Induced by Calcium

Liu, Q., Graeff, R. M., Kriksunov, I. A., Lam, C. M. C., Lee, H. C., & Hao, Q. (2008) · Biochemistry · doi:10.1021/bi801642q · Cited by 14

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Gimsing, P., Plesner, T., Nahi, H., Lokhorst, H. M., Valentin, M.-L., Lisby, S., & Richardson, P. G. G. (2011) · Blood · doi:10.1182/blood.v118.21.1873.1873 · Cited by 6

Mechanisms in removal of tumor by antibody

Stevenson, G. T., Bell, A. J., Evans, T. R. J., French, R. R., Glennie, M. J., Hamblin, T. J., Kan, K., & Mead, G. M. (1994) · Cell Biophysics · doi:10.1007/bf02789214 · Cited by 3

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521

CD38 antibodies in multiple myeloma: back to the future

van de Donk, N. W. C. J., Richardson, P. G. G., & Malavasi, F. (2017) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 495

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 357

Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond

van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353

CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels

Chini, C. C. S., Peclat, T. R., Warner, G. M., Kashyap, S., Espindola-Netto, J. M., de Oliveira, G. C., Gomez, L. S., Hogan, K. A., Tarragó, M. G., Puranik, A. S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00298-z · Cited by 349

The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases

Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 348

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity

Piedra-Quintero, Z. L., Wilson, Z., Nava, P., & Guerau‐de‐Arellano, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.597959 · Cited by 351

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Seckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A. L., Lipp, S., Merino, J., Prósper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 313

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297

Mantle Cell Lymphoma

Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 276

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Flores-Montero, J. A., Tute, R. M. D., Paiva, B., Pérez, J. J., Böttcher, S., Wind, H., Sanoja-Flores, L., Puig, N., Lécrevisse, Q., Vídriales, M., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21265 · Cited by 263

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252

Evolutionary biology of high-risk multiple myeloma

Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 240

Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells

Ochoa, M. C., Minute, L., Rodríguez, I., Garasa, S., Pérez-Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.6 · Cited by 236

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241

The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging

Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Moreno, L., Pérez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodríguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204

Targeting B-Cell Maturation Antigen in Multiple Myeloma

Tai, Y., & Anderson, K. C. (2015) · Immunotherapy · doi:10.2217/imt.15.77 · Cited by 189

Critical Role of the cGAS-STING Pathway in Doxorubicin-Induced Cardiotoxicity

Luo, W., Zou, X., Wang, Y., Dong, Z., Weng, X., Pei, Z., Song, S., Zhao, Y., Wei, Z., Gao, R., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321587 · Cited by 183

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Martin, T. G., Baz, R., Benson, D. M., Lendvai, N. K., Wolf, J. L., Münster, P. N., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740787 · Cited by 169

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R. R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 167

Treatment options for relapsed and refractory multiple myeloma

Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 157

Cancer immunoediting and immune dysregulation in multiple myeloma

Nakamura, K., Smyth, M. J., & Martinet, L. (2020) · Blood · doi:10.1182/blood.2020006540 · Cited by 155

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

Richardson, P. G. G., Perrot, A., Miguel, J. F. S., Beksaç, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., Huang, J. S.-Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00019-5 · Cited by 129

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Zhu, C. Y., Song, Z., Wang, A., Srinivasan, S. S., Yang, G., Greco, R., Theilhaber, J., Shehu, E., Wu, L., Yang, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01771 · Cited by 117

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Martin, T. G., Dimopoulos, M. A., Mikhael, J. R., Yong, K., Capra, M., Facon, T. T. F., Hájek, R., Špıčka, I., Baker, R. I., Kım, K., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00797-8 · Cited by 100

Blockade of CD38 diminishes lipopolysaccharide-induced macrophage classical activation and acute kidney injury involving NF-κB signaling suppression

Shu, B., Ye, F., Gui, Y., Lu, Q., Wei, W., Xue, X., Sun, X., He, W., Yang, J., & Dai, C. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.10.014 · Cited by 100

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Jayaweera, S. P. E., Kanakanamge, S. P. W., Rajalingam, D., & Silva, G. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740796 · Cited by 101

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Lonial, S., Durie, B. G. M., Palumbo, A. P., & Miguel, J. F. S. (2015) · Leukemia · doi:10.1038/leu.2015.223 · Cited by 95

Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies

Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan‐Halevy, I., Rosenblum, D., Goldsmith, M., Avigdor, A., Benjamini, O., Bairey, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519273113 · Cited by 97

Immunomodulatory effects of CD38-targeting antibodies

van de Donk, N. W. C. J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.005 · Cited by 96

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Mikhael, J. R., Belhadj‐Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., Pour, L., Špıčka, I., Vij, R., Zonder, J. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00478-4 · Cited by 88

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

van der Schans, J. J., van de Donk, N. W. C. J., & Mutis, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01362 · Cited by 88

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84

AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies

Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 83

The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors

Konen, J. M., Fradette, J. J., & Gibbons, D. L. (2019) · Cells · doi:10.3390/cells9010052 · Cited by 82

Isatuximab: First Approval

Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01311-1 · Cited by 79

CD38 and Regulation of the Immune Response Cells in Cancer

Dwivedi, S., Rendon‐Huerta, E. P., Ortiz-Navarrete, V. F., & Montaño, L. F. (2021) · Journal of Oncology · doi:10.1155/2021/6630295 · Cited by 77

Multiple Myeloma Therapy: Emerging Trends and Challenges

Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 89

Immuno-targeting the multifunctional CD38 using nanobody

Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 75

Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells

An, N., Hou, Y. N., Zhang, Q. X., Li, T., Zhang, Q. L., Fang, C., Chen, H., Lee, H. C., Zhao, Y. J., & Du, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00584 · Cited by 77

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Moreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 72

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

Murata, K., McCash, S. I., Carroll, B. L., Lesokhin, A. M., Hassoun, H., Lendvai, N. K., Korde, N., Mailankody, S., Landau, H. J., Koehne, G., et al. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.09.015 · Cited by 71

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 69

Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma

Brivio, E., Baruchel, A., Beishuizen, A., Bourquin, J., Brown, P. A., Cooper, T. M., Gore, L., Kolb, E. A., Locatelli, F., Maude, S. L., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.029 · Cited by 72

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

Fumey, W., Koenigsdorf, J., Kunick, V., Menzel, S., Schütze, K., Unger, M., Schriewer, L., Haag, F., Adam, G., Oberle, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14112-6 · Cited by 69

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells

Matula, Z., Mikala, G., Lukácsi, S., Matkó, J., Kovács, T., Monostori, É., Uher, F., & Valyi-Nagy, I. T. (2021) · Cancers · doi:10.3390/cancers13143461 · Cited by 68

Immune Therapies in Multiple Myeloma

Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

de la Puente, P., Luderer, M. J., Federico, C., Jin, A. Y., Gilson, R. C., Egbulefu, C., Alhallak, K., Shah, S., Muz, B., Sun, J., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.045 · Cited by 67

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

Díaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 66

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 65

Monoclonal antibody therapy in multiple myeloma

Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Zhang, K. W., Stockerl-Goldstein, K. E., & Lenihan, D. J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.002 · Cited by 62

Chimeric Antigen Receptor ( CAR ) therapy for multiple myeloma

Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N., & Luetkens, T. (2016) · British Journal of Haematology · doi:10.1111/bjh.13889 · Cited by 60

Current developments in immunotherapy in the treatment of multiple myeloma

Köhler, M., Greil, C., Hudecek, M., Lonial, S., Raje, N. S., Wäsch, R., & Engelhardt, M. M. (2018) · Cancer · doi:10.1002/cncr.31243 · Cited by 58

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 58

Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia

Bayón-Calderón, F., Toribio, M. L., & González-García, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207685 · Cited by 62

Immunometabolism: signaling pathways, homeostasis, and therapeutic targets

Xu, R., He, X., Xu, J., Yu, G., & Wu, Y. (2024) · MedComm · doi:10.1002/mco2.789 · Cited by 64

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0857-2 · Cited by 54

B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages

Nobari, S. T., Nojadeh, J. N., & Talebi, M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03285-y · Cited by 53

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

Matas‐Céspedes, A., Vidal‐Crespo, A., Rodríguez, V., Villamor, N., Delgado, J., Giné, E., Roca-Ho, H., Menéndez, P. R., Campo, E., López‐Guillermo, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2095 · Cited by 53

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Bisht, K. K., Fukao, T., Chiron, M., Richardson, P. G. G., Atanackovic, D., Chini, E. N., Chng, W. J., de Velde, H. J. V., & Malavasi, F. (2023) · Cancer Medicine · doi:10.1002/cam4.6619 · Cited by 50

CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy

Poret, N., Fu, Q., Guihard, S., Cheok, M. H.-C., Miller, K., Zeng, G. G., Quesnel, B., Troussard, X., Galiègue‐Zouitina, S., & Shelley, C. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0893 · Cited by 52

Immunotherapies targeting CD38 in Multiple Myeloma

Atanackovic, D., Steinbach, M. N., Radhakrishnan, S. V., & Luetkens, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1217374 · Cited by 51

Isatuximab: A Review of Its Use in Multiple Myeloma

Frampton, J. E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00827-0 · Cited by 51

CD38 as an immunotherapeutic target in multiple myeloma

Bonello, F., D’Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & Gay, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1544240 · Cited by 50

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

Harrison, S. J., Perrot, A., Alegre, A. M., Simpson, D., Wang, M. C., Spencer, A. G., Delimpasi, S., Hulin, C., Sunami, K., Facon, T. T. F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17499 · Cited by 48

Emerging drugs and combinations to treat multiple myeloma

Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

Bonello, F., Mina, R., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers12010015 · Cited by 45

Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism

Spatola, B. N., Lerner, A. G., Wong, C., Cruz, T. D., Welch, M., Fung, W., Kovalenko, M. A., Losenkova, K., Yegutkin, G. G., Beers, C., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1838036 · Cited by 46

Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment

Das, S., Juliana, N., Yazit, N. A. A., Azmani, S., & Abu, I. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031649 · Cited by 46

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Vincenti, F. G., Bestard, O., Brar, A., Cruzado, J. M., Serón, D., Gaber, A. O., Ali, N. M., Tambur, A. R., Lee, H., Abbadessa, G., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000287 · Cited by 44

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Radocha, J., van de Donk, N. W. C. J., & Weisel, K. C. (2021) · Cancers · doi:10.3390/cancers13071571 · Cited by 45

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 41

Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies

Bisht, K. K., Walker, B. A., Kumar, S. K., Špıčka, I., Moreau, P., Martin, T. G., Costa, L. J., Richter, J. R., Fukao, T., Macé, S., et al. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1983427 · Cited by 41

New Biological Therapies for Multiple Myeloma

Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47

CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions

Liao, S., Xiao, S., Chen, H., Zhang, M., Chen, Z., Long, Y., Gao, L., Zhu, G., He, J., Peng, S., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22677 · Cited by 41

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

de Acha, O. P., Reiman, L. T., Jayabalan, D. S., Walker, Z. J., Bosma, G., Keller, A. L., Parzych, S. E., Abbott, D., Idler, B. M., Ribadeneyra, D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010162 · Cited by 40

Effect of CD38 on B‐cell function and its role in the diagnosis and treatment of B‐cell‐related diseases

Zeng, F., Zhang, J., Jin, X., Liao, Q., Chen, Z., Luo, G., & Zhou, Y. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30760 · Cited by 39

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity

Menzel, S., Schwarz, N., Haag, F., & Koch‐Nolte, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00266 · Cited by 38

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

Varga, C., Laubach, J. P., Anderson, K. C., & Richardson, P. G. G. (2018) · British Journal of Haematology · doi:10.1111/bjh.15116 · Cited by 39

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40

Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization

Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39

Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma

Lee, H. T., Kim, Y.-J., Park, U. B., Jeong, T. J., Lee, S. H., & Heo, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.048 · Cited by 37

The Link Between Endoplasmic Reticulum Stress and Lysosomal Dysfunction Under Oxidative Stress in Cancer Cells

Vietri, M., Miranda, M. R., Amodio, G., Ciaglia, T., Bertamino, A., Campiglia, P., Remondelli, P., Vestuto, V., & Moltedo, O. (2025) · Biomolecules · doi:10.3390/biom15070930 · Cited by 39

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

Atanackovic, D., Yousef, S., Shorter, C., Tantravahi, S. K., Steinbach, M. N., Cardenas, F. I., Sborov, D. W., Radhakrishnan, S. V., Chiron, M., Miles, R. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0536-3 · Cited by 37

Isatuximab for the treatment of relapsed/refractory multiple myeloma

Richardson, P. G. G., Beksaç, M., Špıčka, I., & Mikhael, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1841747 · Cited by 37

Targeting NAD+ metabolism: dual roles in cancer treatment

Yong, J., Cai, S., & Zeng, Z.-L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269896 · Cited by 37

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Park, P. U., Blanc, V., Deckert, J., Lejeune, P., Bartle, L. M., Skaletskaya, A., Mayo, M., Zhang, C., Wetzel, M.-C., Tavares, D., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2756.2756 · Cited by 6

Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.

Hann, B. C., Cai, T., Wang, D., Hom, Y. K., Aftab, B. T., Martin, T. G., & Wolf, J. L. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5469 · Cited by 2

Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.

Wetzel, M.-C., Nicolazzi, C., Vallée, F., Deckert, J., Dumontet, C., Pleșa, A., Kannt, A., Mikol, V., Chiron, M., Vincent, L., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4735 · Cited by 3

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Peipp, M., de Weers, M., Beyer, T. D., Repp, R., Parren, P. W. H. I., Valerius, T., & van de Winkel, J. G. J. (2005) · Blood · doi:10.1182/blood.v106.11.3377.3377 · Cited by 1

Abstract #2048: SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.

Deckert, J., Yi, Y. W., Chicklas, S., Mayo, M., Chittenden, T. W., & Park, P. U. (2009) · Cancer Research